Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Bluebird bio Inc

BLUE
Current price
0.52 USD +0.038 USD (+7.92%)
Last closed 0.49 USD
ISIN US09609G1004
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 97 810 224 USD
Yield for 12 month -82.62 %
1Y
3Y
5Y
10Y
15Y
BLUE
21.11.2021 - 28.11.2021

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts. Address: 455 Grand Union Boulevard, Somerville, MA, United States, 02145

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

2.75 USD

P/E ratio

Dividend Yield

Current Year

+29 497 000 USD

Last Year

+3 597 000 USD

Current Quarter

+16 101 000 USD

Last Quarter

+18 573 000 USD

Current Year

-4 030 000 USD

Last Year

-6 480 000 USD

Current Quarter

-12 845 000 USD

Last Quarter

-7 291 000 USD

Key Figures BLUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -302 105 984 USD
Operating Margin TTM -548.99 %
PE Ratio
Return On Assets TTM -36.24 %
PEG Ratio 0.32
Return On Equity TTM -186.7 %
Wall Street Target Price 2.75 USD
Revenue TTM 54 900 000 USD
Book Value 0.27 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 133.7 %
Dividend Yield
Gross Profit TTM -247 244 000 USD
Earnings per share -2.47 USD
Diluted Eps TTM -2.47 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BLUE

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BLUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1544:1000
Payout Ratio
Last Split Date 05.11.2021
Dividend Date

Stock Valuation BLUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 10.9597
Price Sales TTM 1.7816
Enterprise Value EBITDA -1.5046
Price Book MRQ 0.7464

Financials BLUE

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BLUE

For 52 weeks

0.46 USD 5.53 USD
50 Day MA 0.77 USD
Shares Short Prior Month 49 371 558
200 Day MA 1.11 USD
Short Ratio 4.75
Shares Short 48 403 895
Short Percent 26.64 %